NovoCure Limited (NVCR)
| Market Cap | 6.99B |
| Revenue (ttm) | 537.84M |
| Net Income (ttm) | -92.53M |
| Shares Out | 118.99M |
| EPS (ttm) | -0.88 |
| PE Ratio | n/a |
| Forward PE | 909.09 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 692,412 |
| Open | 58.45 |
| Previous Close | 58.45 |
| Day's Range | 57.99 - 59.82 |
| 52-Week Range | 56.39 - 120.03 |
| Beta | 0.83 |
| Analysts | Buy |
| Price Target | 105.50 (+79.61%) |
| Earnings Date | Apr 27, 2023 |
About NVCR
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cance... [Read more]
Financial Performance
In 2022, Novocure's revenue was $537.84 million, an increase of 0.53% compared to the previous year's $535.03 million. Losses were -$92.53 million, 58.6% more than in 2021.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for NVCR stock is "Buy." The 12-month stock price forecast is $105.5, which is an increase of 79.61% from the latest price.
News
Novocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure today announced the 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program.
Novocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure (NASDAQ:NVCR) today announced the reimbursement and availability of Optune together with temozolomide (TMZ) for the treatment of adult patients w...
Novocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure announced that the final patient has enrolled in the pivotal METIS study.
NovoCure (NVCR) Reports Q4 Loss, Misses Revenue Estimates
NovoCure (NVCR) delivered earnings and revenue surprises of -12.50% and 0.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Allyson J. Ocean, M.D., Joins Novocure Board of Directors
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Allyson J. Ocean, M.D., has been elected to Novocure's Board of Directors. Dr. Ocean brings decades of experience in oncology to Novocure.
Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
Analysts Estimate NovoCure (NVCR) to Report a Decline in Earnings: What to Look Out for
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure today announced that the final patient has been enrolled in the pivotal PANOVA-3 study.
Novocure Announces Organizational Changes to Prepare for Future Growth
ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced organizational changes to prepare for future growth, effective Jan. 17.
Novocure Announces Preliminary Full Year and Fourth Quarter 2022 Net Revenues and Provides Company Update
ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial results and operational updates for the quarter and full year ended December 31, 2022. Novo...
NovoCure (NVCR) Stock Soars 50% on Positive Clinical Trial Results
What's driving the NovoCure (NASDAQ: NVCR) stock price by more than 50% today? The big news concerns NovoCure's proposed treatment for a particular type of lung cancer.
Novocure, Zai shares rally after lung-cancer treatment meets primary endpoint in study
Shares of Novocure Ltd. NVCR, +3.81% soared 71.5% in premarket trading on Thursday after the company said the experimental non-small cell lung cancer treatment it's developing with Zai Lab Ltd.
Novocure Announces Pivotal LUNAR Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint
ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced the LUNAR study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement ...
Novocure to Participate in 41st Annual J.P. Morgan Healthcare Conference
ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today it will participate in the 41st Annual J. P. Morgan Healthcare Conference on January 10-11, 2023. William Doyle, Novocure'...
Novocure's Optune® Approved in Canada for the Treatment of Newly Diagnosed and Recurrent Glioblastoma
ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced that Health Canada has approved Optune® for the treatment of newly diagnosed and recurrent glioblastoma (GBM). GBM is the ...
Novocure to Participate in 34th Annual Piper Sandler Healthcare Conference
ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today it will participate in the 34th Annual Piper Sandler Healthcare Conference on December 1, 2022. William Doyle, Novocure's ...
Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting
ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced 25 abstracts on Tumor Treating Fields (TTFields) therapy will be featured at the Society for Neuro-Oncology (SNO) 2022 Ann...
Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada
ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced it has opened a new office in Montreal to expand and support its growing business in Canada. Novocure is a global oncology...
Novocure Secures CE Mark for New Array
ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced receipt of CE Mark for its new polymer-based transducer array, called the flex array, designed for more efficient Tumor Tr...
NovoCure (NVCR) Reports Q3 Loss, Lags Revenue Estimates
NovoCure (NVCR) delivered earnings and revenue surprises of 16.67% and 2.85%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Novocure Reports Third Quarter 2022 Financial Results
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure reported financial results for the quarter ended September 30, 2022.
Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR #TTFields--Novocure announced 11 poster presentations on Tumor Treating Fields (TTFields) will be featured at the ASTRO 2022 Annual Meeting.
Novocure Announces Review Article of Anti-Cancer Mechanisms of Action of Tumor Treating Fields Published in Journal of Molecular Cell Biology
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--A review article of anti-cancer mechanisms of action of Tumor Treating Fields has been published in the Journal of Molecular Cell Biology.
Novocure Launches Campaign to Drive Awareness and Understanding of Tumor Treating Fields Therapy
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR #TumorTreatingFieldsTherapy--Novocure launched a campaign to drive awareness and understanding of Tumor Treating Fields (TTFields) therapy as a distinct an...
Novocure to Report Third Quarter 2022 Financial Results
ROOT, Switzerland--(BUSINESS WIRE)---- $NVCR--Novocure will report financial results for the third quarter 2022 on Thursday, October 27, 2022, before the U.S. financial markets open.